A look at Johnson & Johnson 1st-quarter sales

A look at health care giant Johnson & Johnson's first-quarter revenue by division and for selected products and categories:

CONSUMER HEALTH PRODUCTS 1Q 2013 1Q 2012 Change

U.S. Total $1.35 B $1.32 B up 2.4 percent

International Total $2.33 B $2.28 B up 2.1 percent

Worldwide Total $3.68 B $3.6 B up 2.2 percent

Nonprescription drugs/nutritionals-U.S. $436 M $381 M up 14.4 percent

PRESCRIPTION DRUGS 1Q 2013 1Q 2012 Change

U.S. Total $3.47 B $3.03 B up 14.7 percent

International Total $3.3 B $3.11 B up 6.1 percent

Worldwide Total $6.77 B $6.13 B up 10.4 percent

Remicade (immune disorders) $1.6 B $1.52 B up 5.2 percent

Stelara (psoriasis) $346 M $221 M up 57 percent

Prezista (HIV) $367 M $324 M up 13.3 percent

Concerta (attention deficit disorder) $256 M $308 M down 16.9 percent

Risperdal Consta (schizophrenia) $335 M $361 M down 7.2 percent

Invega Sustenna (schizophrenia) $284 M $161 M up 76.4 percent

Zytiga (prostate cancer) $344 M $200 M up 72 percent

Velcade (multiple myeloma) $353 M $353 M flat

Procrit (anemia from cancer/dialysis) $378 M $376 M up 0.5 percent

Xarelto (clot prevention) $158 M $27 M up 485 percent

MEDICAL DEVICES & DIAGNOSTICS 1Q 2013 1Q 2012 Change

U.S. Total $3.21 B $2.88 B up 11.4 percent

International Total $3.86 B $3.53 B up 9.1 percent

Worldwide Total $7.06 B $6.41 B up 10.2 percent

Diabetes Care-global $600 M $670 M down 10.4 percent

Orthopedic Products-global $2.39 B $1.49 B up 59.7 percent

TOTAL SALES 1Q 2013 1Q 2010 Change

U.S.

$8.03 B $7.22 B up 11.2 percent

International $9.48 B $8.92 B up 6.3 percent

Worldwide Total $17.51 B $16.14 B up 8.5 percent

Note: Orthopedic sales jumped mainly due to the huge Synthes acquisition.

____

Source: Johnson & Johnson